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AbstrAct
Multiple myeloma cell growth relies on intrinsic aggressiveness, due to a high 
karyotypic instability, or on the support from bone marrow (BM) niche. 
We and other groups have provided evidences that Notch signaling is related to 
tumor cell growth, pharmacological resistance, localization/recirculation in the BM 
and bone disease. 
This study indicates that high gene expression levels of Notch signaling members 
(JAG1, NOTCH2, HES5 and HES6) correlate with malignant progression or high-risk 
disease, and Notch signaling may participate in myeloma progression by increasing 
the BM levels of interleukin-6 (IL-6), a major player in myeloma cell growth and 
survival. Indeed, in vitro results, confirmed by correlation analysis on gene expression 
profiles of myeloma patients and immunohistochemical studies, demonstrated that 
Notch signaling controls IL-6 gene expression in those myeloma cells capable of IL-6 
autonomous production as well as in surrounding BM stromal cells. In both cases 
Notch signaling activation may be triggered by myeloma cell-derived Jagged ligands. 
The evidence that Notch signaling positively controls IL-6 in the myeloma-associated 
BM makes this pathway a key mediator of tumor-directed reprogramming of the bone 
niche. 
This work strengthens the rationale for a novel Notch-directed therapy in multiple 
myeloma based on the inhibition of Jagged ligands.
INtrODUctION
Multiple Myeloma (MM) is a clonal B-cell 
malignancy that affects post-germinal center plasma 
cells (PCs) and represents about 13% of all hematologic 
cancers [1]. Plasma cell dyscrasias such as MM are 
characterized by clonal proliferation of PCs in the bone 
marrow (BM). The interaction between MM cells and BM 
niche components plays a key role in MM [2, 3]. Indeed, 
MM cells and BM stromal cells (BMSCs) interact through 
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adhesion molecules and soluble factors (such as cytokines 
and growth factors) [4]. The activation of BMSCs 
mediated by neoplastic cells further supports the survival 
and growth of tumor cells and promotes the osteolytic 
damage associated with MM [2, 3]. 
Interleukin-6 (IL-6) is one of the most important 
factors for MM cell growth and survival in vivo [4, 
5]. There are two different sources of IL-6 in MM that 
promote tumor development and maintenance in vivo: 
autocrine IL-6 derived from myeloma cells [6-9] and 
paracrine IL-6 derived from non-malignant cells of the 
BM niche [10-12]. BMSCs produce high levels of IL-6 
that directly stimulates survival and proliferation of 
malignant PCs [5]. The relevance of IL-6 in MM disease 
is supported by multiple lines of evidence. Specifically, 
high levels of IL-6 in the serum of MM patients: i) directly 
correlate with tumor burden and disease severity [13, 14]; 
ii) promote MM progression [15, 16] through pleiotropic 
effects on cell proliferation, survival, migration and 
resistance to conventional chemotherapy; and iii) may 
represent a negative prognostic factor [17-19]. Moreover, 
anti-IL-6 monoclonal antibody exposure may transiently 
reverse MM manifestations [20].
Several studies indicate that intracellular production 
of IL-6 is mainly regulated at a transcriptional level. In 
particular, the nuclear factor kB (NF-kB), activated by 
diverse stimuli such as interleukin-1 (IL-1) and tumor 
necrosis factor a (TNFα) [21-24], plays a key role in 
regulating IL-6 expression. Moreover, recent evidence 
has further highlighted the ability of the Notch pathway to 
control IL-6 expression in hematopoietic stem cells [25, 
26] and in macrophages [27]. 
In mammals, the Notch pathway consists of four 
transmembrane receptors (NOTCH1-4) and two families 
of ligands, the Serrate-like ligands (JAGGED1 and 2) 
and the Delta-like-ligands (DLL-1/3/4) [28]. Ligand 
binding induces two proteolytic cleavage events that 
release the cytoplasmic portion of the receptors (the active 
intracellular Notch, ICN), allowing its translocation to 
the nucleus [29]. Nuclear ICN regulates transcription of 
several target genes involved in physiologic development 
and cancer, such as the transcriptional factors Hairy 
and Enhancer of Split (HES1-7 and HEY1-2,L) [30]. 
Deregulation of the Notch pathway has been associated 
with the pathogenesis of several solid tumors (i.e. 
glioblastoma, melanoma and breast, colorectal and 
pancreatic cancer) [31] and hematologic malignancies (i.e. 
T-ALL, B-ALL, AML, B-CLL and MM) due to activating 
mutations or putative epigenetic mechanisms [28, 32-35] . 
Notably, immunohistochemical studies have shown 
that MM cells overexpress the receptors NOTCH1 and 2 
and the two ligands JAGGED1 and JAGGED2 [36-39]. 
In particular, JAGGED1 is overexpressed during the 
progression from monoclonal gammopathy of uncertain 
significance (MGUS) to MM [38], whereas JAGGED2 
dysregulation is an earlier event that precedes MGUS 
and is correlated with disease stage [40]. The molecular 
mechanisms underlying JAGGED2 dysregulation have 
been investigated and involve epigenetic alterations [36] 
or overexpression of the ubiquitin ligase Skeletrophin, 
acting in JAGGED2 processing [39]. 
Several lines of evidence from our work and other 
groups highlighted the importance of Notch signaling 
in MM pathogenesis [28, 41], thus providing a strong 
rationale for its use as a possible therapeutic target. Indeed, 
Notch inhibition induces tumor cell apoptosis, reduces 
drug resistance [42-44], self-renewal [45], and bone 
disease [46-48], and impairs the migration/recirculation 
of malignant PCs to the BM [49]. 
This work builds upon experimental evidence 
showing that Notch pathway dysregulation in myeloma 
cells mediates key interactions between MM cells and 
BMSCs. Additionally, upregulation of Notch signaling 
members correlates with MM progression or high-risk 
disease. Here, we provide new evidences that upregulated 
Notch signaling supports MM cell growth and contributes 
to disease progression by promoting activation of an IL-6 
autocrine loop in MM and favoring IL-6 paracrine release 
by the surrounding BMSCs. 
rEsULts
Notch signaling is deregulated during MM cell 
progression and in high-risk disease
To investigate transcript expression levels of Notch 
signaling members, we analyzed highly purified CD138+ 
PC samples from primary MM patients. Gene expression 
profiling (GEP) analysis carried out in a proprietary data 
set of 129 MM, 24 primary plasma cell leukemia (pPCL) 
patients and 4 normal controls revealed that the Notch 
transcriptional target HES5 and the Notch ligand JAG1 
are overexpressed in the different types of PC dyscrasias 
compared to normal controls, reaching a higher expression 
level in pPCLs (Figure 1A).
In addition, we analyzed the expression patterns of 
Notch signaling members in 129 MM cases molecularly 
stratified on the basis of the presence of the main IgH 
chromosomal translocations and cyclin D expression 
(TC classification) [50] including 33 TC1, 28 TC2, 38 
TC3, 19 TC4 and 6 TC5 cases. Expression of NOTCH2 
was significantly increased in the six TC5 MM patients 
(Figure 1B), which carry the high-risk translocations 
t(14;16)(q32;q23) and t(14;20)(q32;q11). Also, two Notch 
transcriptional target genes, HES5 and HES6, show higher 
expression levels in TC5 compared to other TC classes. 
GEP results were validated by qRT-PCR (Figure S1 and 
Supplemental Information).
Patients affected by pPCL or belonging to the TC5 
subgroup are characterized by the presence of highly 
Oncotarget56015www.impactjournals.com/oncotarget
proliferative and aggressive tumor cells. These malignant 
cells show a reduced dependency on signals provided by 
the BM, mainly IL-6, thus prompting us to hypothesize 
that hyperactive Notch signaling may participate in 
MM progression by compensating or activating IL-6 
proliferative signaling. 
Notch activity is necessary for the acquisition of 
IL-6 independency
To test the hypothesis that IL-6 independency 
could occur through cell-autonomous compensatory 
mechanisms, we analyzed the Notch signaling pathway 
activity in the human myeloma cell lines (HMCLs) CMA-
03 and CMA-03/06, a cell model of MM acquisition of 
IL-6 independency previously established by our group 
[51, 52]. This model comprises the CMA-03 parental cells, 
which rely on IL-6 stimulation for cell proliferation, and 
CMA-03/06 cells, which are an IL-6 independent and 
unresponsive variant obtained after 4 months of culture 
with decreasing concentrations of IL-6. We reasoned that, 
if the acquisition of IL-6 independency could be due to 
the possible activation of Notch signaling, then: 1) the 
progression to IL-6 independency of CMA-03/06 cells 
should be accompanied by Notch signaling activation and 
reverted by Notch signaling inhibition; 2) CMA-03 cells 
may acquire IL-6-independency by upregulating Notch 
signaling. 
Figure 1: NOtcH related genes are overexpressed during MM progression. Microarray expression levels of genes belonging 
to the NOTCH pathway in purified plasma cells (PCs) from normal controls (N), multiple myeloma (MM), and primary plasma cell 
leukemia (pPCL) samples. The absolute expression levels (linear scale) of NOTCH2, JAG1, HES5 and HES6 transcripts were assessed by 
means of microarray analysis. Box plot representations of messenger RNA expression levels in A. PC samples from 4 healthy donors (N), 
129 MM and 24 pPCL patients; and b. 129 MM samples stratified according to TC classification (33 TC1, 28 TC2, 38 TC3,19 TC4 and 6 
TC5). Kruskal-Wallis test was applied to assess statistical significance of differential gene expression profiles between all PC dyscrasias and 
MM TC classes, respectively. Dunn’s test was performed for nonparametric pairwise multiple comparisons between all analyzed groups in 
PC dyscrasia and MM samples datasets and the Benjamini-Hochberg correction was applied for multiple comparisons. Statistical analysis 
indicates a significant p-value between N and pPCL (p = 0.0211) for JAG1; N and pPCL (p = 0.0071), MM and pPCL (p = 0.0043) for 
HES5; TC5 and the other TC classes (TC1 p = 0.0068, TC2 p = 0.0215; TC3 p = 0.0150; TC4 p = 0.0112) for NOTCH2; TC5 and TC1(p = 
0.0056) for HES5; TC5 and TC3 (p = 0.0239) for HES6, respectively.
Oncotarget56016www.impactjournals.com/oncotarget
Figure 2: Notch activity reduces the dependency of MM cell lines from IL-6. The contribution of Notch and IL-6 to MM 
cells growth was evaluated. A. The expression levels of Notch receptors (NOTCH1-4), Notch ligands (JAGGED1-2 and DLL1,3,4) and 
Notch transcriptional target genes, HES1 and HES6, were assessed in the two cell lines, CMA-03 and CMA-03/06, by qRT-PCR. Results 
were calculated by the 2-ΔCt formula and SDs were calculated from 3 independent experiments. Statistical analysis was performed using 
Student’s t-test: * = p < 0.05;** = p < 0.01;*** = p < 0.001. b.-D. Cell growth analysis of CMA-03/06 (B), OPM2 (C) and U266 (D) cells 
treated with or without DAPT 50µM and/or IL-6 for 96h. Mean values ± SD are shown. Statistical analysis was performed using ANOVA 
and Tukey test: ** = p < 0.01. E.-F. CMA-03 (E) and XG-1 (F) cells were treated with 5µg/ml soluble JAGGED1 ligand (J1) for 4-5 days: 
J1 stimulation is able to compensate for IL-6 withdrawal. SD were calculated from 3 independent experiments and statistical analysis was 
performed using ANOVA and Tukey test: * = p < 0.05;** = p < 0.01;*** = p < 0.001. 
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To address the first issue, we measured by qRT-PCR 
the relative expression levels of Notch signaling members 
in CMA-03 and CMA-03/06 cells. As shown in Figure 
2A, we found significant differences in the expression 
levels of Notch receptors (NOTCH1-4), Notch ligands 
(JAGGED1-2 and DLL1,3,4) and Notch transcriptional 
target genes, HES1 and HES6, used as a measure of Notch 
activation, in the two cell lines. In Figure S2 we showed 
the expression levels of the above reported genes in CMA-
03/06 normalized to CMA-03 cells. Increased expression 
of Notch receptors and ligands in CMA-03/06 cells was 
associated with considerable increased levels of HES1 
and HES6 transcripts. We confirmed Notch signaling 
activation by analyzing the protein expression of the 
NOTCH2 active form (the most expressed isoform) and 
the Notch transcriptional target, HES1, in Western blot 
(Figure S3). These results indicate that the acquisition 
of IL-6 independent cell growth was associated with a 
significant increase in Notch pathway activity. 
To confirm that Notch signaling was necessary 
to maintain IL-6 independency, we inhibited Notch 
activation in IL-6 independent MM cells by means of 
γ-Secretase inhibitor (i.e. DAPT). To this purpose, CMA-
03/06 cells were treated for 96 hours with 50µM DAPT, 
10ng/ml IL-6, or a combination of both compounds; 
the respective vehicles, DMSO and BSA, were used as 
controls. The DAPT-mediated Notch withdrawal was 
confirmed by evaluating the expression of the Notch 
target gene HES6 by qRT-PCR (Figure S4). Figure 2B 
shows that DAPT treatment significantly reduced cell 
proliferation, which could be largely recovered by IL-6 
administration. It should be noted that exogenous IL-6 was 
capable of stimulating CMA-03/06 cell proliferation when 
Notch signaling is depleted, although it was ineffective 
Figure 3: Notch drives MM cell-autonomous production of IL-6 and stimulates their proliferation. U266 cells were 
transfected with two specific siRNAs targeting JAGGED1 and JAGGED2 (J1/2) or the corresponding scrambled control (Scr). A. 
Confirmation of J1/2 silencing efficiency in U266 cells was obtained by qPCR measurements of relative gene expression variation 
of JAGGED1 and JAGGED2 and Notch target genes HES1 and HES6 in cells transfected with siRNA against J1/2 compared to cells 
transfected with scrambled control, calculated by the 2-ΔΔCt formula. IL-6 expression levels were also analyzed. SDs were calculated from 3 
independent experiments. Two-tailed t-test confirmed statistically significant downregulation of the genes tested; b. Western blot confirmed 
that JAG1, JAG2 and HES1 are downregulated in silenced U266; c. Histograms display the levels of intracellular IL-6 analyzed by flow 
cytometry in U266-J1/2kd or U266-Scr in single culture (black lines), the isotype matched control is shown in gray. ΔGeoMFI were 
obtained by subtracting the appropriate isotype control from the positive signal. Histograms are representative of 3 experiments with similar 
results. D. J1/2 silencing in U266 cells caused a significant decrease in cell proliferation. Mean values ± SD are shown. Statistical analysis 
was performed using two-tailed t-test: ** = p < 0.01; E. Luciferase reporter assay showing that both ICN1 and ICN2 are able to boost the 
activity of IL6 promoter. Mean values ± SD are shown. Statistical analysis was performed using one-tailed, unpaired t-test * = p < 0.05.
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when Notch signaling is active. Therefore, CMA-03/06 
cells regain both responsiveness and dependency on IL-6 
when deprived of Notch proliferative stimuli, indicating 
that Notch signaling may compensate IL-6 activity. The 
results obtained in CMA-03/06 cells were confirmed in 
two other IL-6-independent HMCLs, OPM2 and U266, 
in which decreased cell proliferation induced by Notch 
withdrawal (DAPT; Figure S4) was reverted by IL-6 
stimulation (Figure 2C-2D). 
To verify if Notch signaling was sufficient to 
induce IL-6 independent cell growth in CMA-03 cells, we 
activated endogenous Notch signaling by stimulation with 
soluble JAGGED1 [40, 46]. For this purpose, CMA-03 
cells were treated with 5 µg/ml soluble JAGGED1 ligand 
in the presence or absence of IL-6 (10 µg/ml). Jagged1 
stimulation was able to compensate for IL-6 withdrawal 
with a complete recovery of cell growth (Figure 2E). This 
finding was confirmed in another IL-6-dependent HMCL, 
XG-1 (Figure 2F; Figure S5). In this case, JAGGED1-
mediated Notch stimulation recovered 45% of cell growth 
in the absence of IL-6, indicating that Notch signaling can 
compensate for the lack of IL-6 proliferative stimulus in 
IL-6 dependent MM cell lines. 
Notch signaling promotes MM cell-autonomous 
IL-6 production
To investigate whether Notch signaling may 
promote endogenous IL-6 expression, we took advantage 
of U266 cell line, a cellular model of MM characterized 
by IL-6 independency due to autocrine production 
of IL-6 [53]. We used a previously validated genetic 
Notch inhibitory approach based on the knockdown 
of JAGGED1 and 2 (J1/2) ligands [46]. The efficacy of 
J1/2 silencing was measured by assessing the decrease in 
JAG1, JAG2, HES1 and HES6 gene expression levels by 
Figure 4: bMscs produce IL-6 and support MM cell growth in a Notch-dependent manner. We evluated the contribution 
of the Notch pathway on the ability of stromal cells to support MM cell growth. A. Confirmation of NOTCH1 inhibition in HS5-N1kd by 
qPCR measurements of NOTCH1, HES6 and IL-6 gene expression. HS5-N1kd cells were compared to HS5-Scr control cells. Fold changes 
were calculated by the 2-ΔΔCt formula as reported above. SD were calculated from 3 independent experiments. b. Histograms display the 
levels of intracellular IL-6 (black line) analyzed by flow cytometry in HS5-Scr or HS5-N1kd cells, and an isotype-matched control (gray 
line). ΔGeoMFI were obtained by subtracting the appropriate isotype control from the positive signal. Histograms are representative of 4 
independent experiments with similar results. c. Luciferase assay on the stromal-mimetic cell line NIH3T3 showed that both ICN1 and 
ICN2 promotes the activation of IL6 promoter. Mean values ± SD are shown. Statistical analysis was performed using one-way ANOVA 
and Tukey test: * = p < 0.05; *** = p < 0.001. D. Cell growth analysis of XG-1 cells cultured alone or co-cultured with HS5-Scr or HS5-
N1kd. Mean values ± SD are shown. Statistical analysis was performed using one-way ANOVA and Tukey test: * = p < 0.05, ** = p < 
0.01. E. Confirmation of IL-6 silencing was obtained by qPCR of IL-6 gene expression; fold change was calculated by the 2-ΔΔCt formula 
as reported above. SD was calculated from 3 independent experiments. F. Histograms displayed the levels of intracellular IL-6 (black line) 
analyzed by flow cytometry in HS5-Scr or HS5-IL6kd, and an isotype-matched control (gray line). ΔGeoMFI were obtained by subtracting 
the appropriate isotype control from the positive signal. Histograms are representative of 5 independent experiments with similar results. 
G. Cell growth analysis of XG-1 cells cultured alone or co-cultured with HS5-Scr or HS5-IL6kd. Mean values ± SD are shown. Statistical 
analysis was performed using one-way ANOVA and Tukey test: * = p < 0.05, ** = p < 0.01. 
Oncotarget56019www.impactjournals.com/oncotarget
qRT-PCR (Figure 3A) and JAG1, JAG2 and HES1 protein 
level by western blot (Figure 3B). qRT-PCR and flow 
cytometry demonstrated that J1/J2 silencing reduced both 
IL-6 transcript and protein level by approximately 50% 
(Figure 3A and Figure 3C). For flow cytometric measures 
the statistical significance was calculated on the value of 
geometric mean fluorescent intensity subtracted of the 
appropriate isotype control (ΔGeoMFI) of 3 independent 
experiments (Figure S6). As expected, Notch withdrawal 
through J1/2 knockdown inhibited U266 cell growth by 
approximately 30% (Figure 3D), due to an increase in the 
apoptotic rate and to a partial cell cycle arrest in G0/G1 
phase (Figure S7 and Supplemental Information).
We demonstrated that IL-6 is a Notch transcriptional 
target in MM cells by a dual luciferase assay in U266 cell 
line using an IL-6 reporter (pIL6-luc651) transactivated by 
plasmids carrying the active forms of NOTCH1 (ICN1) 
and NOTCH2 (ICN2). Results, reported in Figure 3E, 
clearly showed that ICN1 and ICN2 can transactivate the 
IL-6 responsive element. 
To investigate the existence of a direct correlation 
between Notch and IL-6 in primary cells from MM 
patients, we analyzed microarray gene expression data 
(GEO dataset No. GSE66293). The analysis on the 
whole dataset failed to identify a statistically significant 
correlation between IL-6 and HES6 (data not shown). 
When patients were stratified according to IL-6 expression 
levels, the results obtained on patients showing the highest 
expression of IL-6 by microarray analysis (Figure S8-A) 
and qRT-PCR (Figure S8-B) indicated positive, even if 
not statistically significant, Pearson’s correlation indexes 
(r = 0.54 and r = 0.71; p = 0.1358 and p = 0.0573, 
respectively), possibly due to the small sample size.
Notch signaling promotes bMsc pro-tumor effect 
by stimulating paracrine IL-6 production
BMSCs are the most important source of IL-6 in 
MM [10, 11]. Therefore, we verified if MM cell-derived 
Jagged ligands could trigger Notch activation in BMSCs 
[49] and boost IL-6 production. 
First, we verified whether IL-6 expression was under 
Notch signaling control in BMSCs. To test this hypothesis, 
Notch signaling was inhibited in the human BMSC line 
HS5 by transfecting NOTCH1-targeting siRNA (HS5-
N1kd). After 96 hours, Notch pathway inhibition in HS5-
N1kd cells was verified by qRT-PCR and analysis of HES6 
gene expression (Figure 4A). HS5-N1kd cells showed a 
significantly reduction in IL-6 gene expression (Figure 
4A), which was confirmed at the protein level by flow 
cytometry (Figure 4B). We confirmed Notch ability to 
transactivate IL-6 promoter in BMSCs by a dual luciferase 
assay in NIH3T3 cell line, a murine easy transfectable 
mimic of BMSCs (Figure 4C). Then, we determined 
whether the Notch-deprived BMSCs maintained the 
ability to support the proliferation of the IL-6-dependent 
cell line XG-1. For this purpose, XG-1 cells were cultured 
for 48h on a layer of GFP+ HS5 cells transfected with 
siRNA targeting Notch1 or with the scrambled (Scr) 
control. XG-1 cells were enumerated by absolute counts 
of GFP- cells by flow cytometry. Results shown in Figure 
4D indicated that HS5-N1kd cells were no longer able 
to support XG-1 cell growth that was comparable to the 
absence of IL-6. This effect was mainly due to increase of 
tumor cells undergoing apoptosis, while no significant cell 
cycle changes were observed (Figure S9).
To confirm that the lack of IL-6 production in HS5-
N1kd cells was responsible for their impaired ability to 
support XG-1 cell proliferation, we knocked down IL-6 
expression in HS5 (HS5-IL6kd) by transfecting them 
with anti-IL-6 siRNA, and co-cultured these or control 
cells (HS5-SCR) with XG-1. IL-6-silencing in HS5 cells, 
confirmed at the mRNA and protein level by qRT-PCR and 
flow cytometry, respectively (Figure 4E and 4F), resulted 
in a significant decrease in cell growth of co-cultured 
XG-1 (Figure 4G). 
MM cell-derived JAGGED ligands activate Notch 
signaling in bMscs, promoting IL-6 production 
and tumor growth
We investigated the possible contribution of 
dysregulated Notch ligands in influencing the ability 
of MM cells to shape the BM microenvironment. The 
expression of JAGGED1 and 2 was inhibited in IL-6-
sensitive HMCLs (XG-1, OPM2 and U266 cells) by 
transfection with J1/2 siRNAs or a SCR control (HMCLs-
J1/2kd or HMCLs-SCR). Transfected MM cell lines were 
co-cultured with GFP+ HS5 to distinguish the two cell 
types. Flow cytometry analyses demonstrated that the 
percentage of IL-6 produced by HS5 cells was increased 
of about the 40-50% when cultured in the presence of 
HMCLs-SCR, but this increase was markedly reversed 
when HS5 were cultured with HMCLs-J1/2kd (Figure 
5A-5C; Figure S10). HS5 cells co-cultured with HMCLs-
J1/2kd were no longer able to support tumor cell growth 
(Figure 5D-5F). We analyzed the outcome on XG-1 cells 
growth since they display a complete dependence on 
the support of HS5 or IL-6 and therefore they represent 
a reliable cell model for MM. Results indicated that 
reduction of XG-1 cell number was due to apoptosis 
(Figure S12). 
We also demonstrated that the observed changes 
in IL-6 protein levels reflected the variations in IL-6 
gene expression by using co-culture systems of human 
OPM2 or U266 cells and murine fibroblasts NIH3T3 that 
allowed us to identify the origin of mRNAs by RT-PCR 
analysis with species-specific primers. Results showed 
that the Notch pathway was activated as demonstrated by 
increased murine hes5 gene expression (Figure 5G-5H) 
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Figure 5: MM-derived JAGGED promotes IL-6 production by bMscs. MM cells are able to shape the BM microenvironment 
and increase IL-6 production. We established co-cultures of MM cells with the BM stromal cell line HS5. Histograms display the levels 
of intracellular IL-6 (black lines) analyzed by flow cytometry in HS5 cells in single culture or after co-culture with XG-1-Scr or XG-1-
J1/2kd (A), OPM2-Scr or OPM2-J1/2kd (b) and U266-Scr or U266-J1/2kd (c) cells, and an isotype-matched control (gray line). ΔGeoMFI 
were obtained by subtracting the appropriate isotype control from the positive signal. Histograms are representative of 3 independent 
experiments for XG-1, 3 for OPM2 and 4 for U266 cells, with similar results. D.-F. Cell growth analysis of HMCLs-J1/2kd or HMCLs-Scr 
cultured alone or co-cultured with HS5 cells, specifically XG-1 (D), OPM2 (E) and U266 cells (F) Mean values ± SD are shown. Statistical 
analysis was performed using one-way ANOVA and Tukey test: * = p < 0.05;** = p < 0.01; *** = p < 0.001. G.-H. qRT-PCR for IL-6 
and HES5 gene expression in NIH3T3 cells co-cultured with OPM2-J1/2kd or OPM2-Scr (G) or U266-J1/2kd or U266-Scr (H) compared 
NIH3T3 cultured alone ( = 1), calculated by the 2−ΔΔCt formula. HES5 was used as a control for pathway activity. Mean values ± SD are 
shown. Statistical analysis was performed using two-tailed t-test: ** = p < 0.01; *** = p < 0.001. 
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and Notch activation was accompanied by an increase in 
murine il-6 gene expression. As expected, JAGGED1-2 
silencing impaired the ability of MM cells to activate the 
Notch pathway in stromal cells, causing a decrease in the 
production of il-6 (Figure 5G-5H). 
Notch signaling withdrawal reduces the release 
of IL-6 in co-cultures of primary MM cells and 
bMscs
We verified whether the ability of BMSCs to release 
IL-6 was dependent on MM cell-mediated Notch signaling 
activation by using primary co-culture systems of highly 
purified CD138+ MM cells and BMSCs from 7 MM 
patients’ BM aspirates, purified as described by Garayoa 
et al. [54]. Co-cultures were maintained for 96 hours in 
the presence or absence of 25 µM DAPT and changes in 
BMSC-mediated IL-6 production were measured by flow 
cytometry. These analyses showed that primary MM cells 
significantly increased the fraction of IL-6-producing 
BMSCs (from 12% to 41% IL-6+ BMSCs, Figure 6A). In 
contrast, DAPT-mediated Notch inhibition significantly 
reduced the proportion of IL-6-producing BMSCs (15% 
IL-6+ BMSCs, Figure 6A), confirming our in vitro findings 
in HS5/HMCL co-cultures. Concerning MM-derived IL-6, 
since primary MM cells do not survive without BMSCs or 
IL-6 stimulation, the evaluation of possible variations in 
IL-6 production by MM cells in the absence of BMSCs 
was not possible. Nevertheless, flow cytometry detection 
of intra-cellular IL-6 allowed us to measure the number 
of IL-6 positive MM cells when they were cultured in the 
presence of BMSCs. We could observe that CD138+ MM 
cells from 3 out of 7 patients expressed appreciable levels 
of IL-6 (ΔGeoMFI >400, Figure 6B). Furthermore, co-
cultured MM cells treated with 25 µM DAPT displayed 
considerably reduced levels of IL-6 expression in each 
of the three IL-6-positive MM patient samples, with a 
median decrease of about 40% (Figure 6B). 
The ability of MM cells to boost IL-6 production 
from BMSC was further confirmed by analysing the 
correlation between IL-6 and HES1 gene expression 
in the dataset of Garcia Gomez et al. [55] including 37 
mesenchymal cell samples from healthy donors or MM 
patients, cultured alone or co-cultured with the MM1S 
cell line. As shown in Figure 6C and 6D, these results 
confirmed a positive correlation between the expression of 
IL-6 and HES1 (r = 0.57 and p = 2.28x10-4) and showed 
IL-6 and HES1 gene expression upregulation upon 
stimulation of mesenchymal cells with MM1S myeloma 
cells.
Finally, we investigated whether there was a 
correlation between Notch activity and IL-6 in the 
endogenous MM BM niche by analyzing BM biopsies 
from 21 MM patients. Immunoreactivity of IL-6 and 
HES6 was assessed by immunohistochemistry (Figure 
6C). In all cases investigated, HES6 immunoreactivity 
was detected both in malignant PCs and in surrounding 
non-myelomatous cells. Moreover, the intensity of the 
immunoreactive signal increased with MM infiltration in 
the BM. IL-6 immunoreactivity is gradually acquired by 
MM cells during BM invasion in neoplastic progression. 
In the early stage of infiltration by MM cells, IL-6 
immunoreactivity was almost exclusively localized in 
non-myelomatous cells, surrounded by small groups 
of MM cells (Figure 6C). Rare MM cells with faint 
cytoplasmic IL-6 immunoreactivity could be detected in 
this stage. IL-6 immunopositive neoplastic cells increased 
in intermediate stages of BM infiltration (up to 30% MM 
cells), and were mainly localized near the bone spicule. In 
late stages, most MM cells were positive for IL-6, the IL-6 
negative cells being no more than 5%. 
No significant differences in IL-6 immunoreactivity 
were observed in positive cells of all investigated cases.
Overall, these results suggest a novel Notch-dependent 
mechanism by which the BM microenvironment may 
support autocrine and paracrine IL-6 production thereby 
promoting MM cell growth (Figure 6D). 
DIscUssION
MM is the second among hematological 
malignancies and affects about 600,000 people every year 
in Europe and the USA [56]. Despite the introduction of 
several new treatments, improving the clinical course 
of disease, myeloma remains an incurable cancer with a 
survival rate of 45% at 5 years [57]. The Notch pathway 
has been proposed as a possible therapeutic target in 
MM [41] due to its role in key aspects of MM, i.e. drug 
resistance [42-44], stemness [45], bone disease [46, 47] 
and migration to BM [49]. 
The aim of the present study was to deepen the 
understanding of the role of Notch signaling upregulation 
[36-40] in MM by investigating its cross talk with the 
chemokine IL-6, a key player of MM progression and 
severity [15-19]. Our first observation was obtained 
by GEP analysis and indicated that the trend of Notch 
signaling activation (evaluated by HES5 expression levels) 
reflected the acquisition of a highly malignant phenotype, 
since it occurred in high-risk cytogenetics MM and PCL 
patients who displayed the highest activation levels. A 
similar trend is associated with gene expression levels 
of the Notch ligand JAGGED1, consistent with the 
immunohistochemistry studies by Skrtic and coworkers 
on JAGGED1 protein [38] and confirming the key role 
played by this ligand in Notch autonomous activation as 
we previously reported [46]. The stratification of MM 
patients according to the TC molecular classification [50] 
indicated an association of the MAF-translocated group 
with the highest NOTCH2 expression levels and increased 
Notch activity (HES5 and HES6 expression levels). This 
was in agreement with the ability of C-MAF and MAFB to 
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activate Notch signaling by transactivating NOTCH2 gene 
expression [58]. Significantly, also MAF translocations are 
frequently associated with high-risk PCLs or aggressive 
forms of de novo MM without preceding MGUS [50, 59]. 
Overall, these results indicate that the activation of 
Notch signaling characterizes the most aggressive form 
of MM and is associated with high-risk disease onset or 
evolution.
Since highly malignant MM cells show a reduced 
dependency on signals provided by the BM, at least in 
part due to the cell-autonomous production of IL-6 [6, 8], 
we wondered if the upregulation of Notch signaling could 
play a role in promoting the malignant progression of MM 
cell by reducing the dependency on signals provided by 
BM such as IL-6. 
This hypothesis was verified in our CMA-03 model 
of MM progression, demonstrating that: 1) the acquisition 
of IL-6 independent cell growth was associated with the 
upregulated expression of Notch receptors and ligands 
together with increased transcription of Notch target 
genes; 2) when stimulated with soluble JAGGED1 
ligands, IL-6-dependent CMA-03 cells acquired the 
ability to grow in the absence of IL-6; and 3) upon DAPT 
administration, IL-6-independent and unresponsive CMA-
03/06 cells recovered IL-6 dependency. The general 
validity of these findings was confirmed on other HMCLs 
and prompted us to postulate that clonal selection leading 
to the development of IL-6-independent MM clones might 
involve the upregulation of the Notch pathway. Thereby, 
these results indicate a novel pathogenic role of Notch 
signaling activation in MM cell consisting in inducing the 
acquisition of IL-6 independency. 
By luciferase reporter assay we demonstrated 
that in MM cells able to autonomously produce IL-
6, such as the U266 cell line [9, 13], the acquisition 
of IL-6 independency may be due to Notch ability to 
transactivate IL-6 promoter. Indeed, in U266 cells Notch 
activity was necessary to maintain the autonomous IL-6 
expression, that significantly decreased upon Notch 
withdrawal induced by RNA interference of JAGGED 
ligands. These in vitro results were confirmed in primary 
cells from three out of seven patients autonomously 
expressing IL-6 (36% IL-6 positive cells on average), 
whose expression declined upon treatment with DAPT 
(14% IL-6 positive on average). Further confirmation 
came from immunohistochemical analysis of BM biopsies 
obtained from MM patients. In particular, we observed 
that the ability of MM cells to produce IL-6 was acquired 
along disease progression through the different stages of 
BM infiltration and was associated with increased Notch 
signaling activation in MM cells. 
Finally, a correlation analysis of gene expression 
levels in primary cells from MM patients, obtained by 
GEP analysis and RT-PCR, suggested that only primary 
MM cells of patients with the higher levels of IL-6 
show a direct correlation between Notch activity (HES6 
gene expression) and IL-6 expression. However, these 
results did not reach the statistical significance possibly 
due to the limited sample size and or the effect of other 
inflammatory stimuli from BM, i.e. NF-κB, affecting IL-6 
expression in primary MM cells. Indeed, according to 
Wongchana and Palaga, Notch signaling is subordinated 
to NF-κB in the activation of IL-6 transcription [60]. A 
full elucidation of the interplay between Notch and BM-
Figure 6: Inhibition of NOtcH signaling abrogates myeloma-induced IL-6 production by bMscs ex-vivo. A. Levels of 
intracellular IL-6 were analyzed by flow cytometry in primary BMSCs co-cultured with CD138+ cells from MM patients in the presence 
or absence of 25μM DAPT. Seven independent experiments were performed and the percentage of IL-6+ BMSCs is shown in the bar 
graph. Statistical analysis was performed using one-way ANOVA and Bonferroni post-test. (* = p < 0.05). b. Analysis of intracellular IL-6 
levels by flow cytometry in primary CD138+ cells co-cultured with BMSCs from MM patients in the presence/absence of 25 μM DAPT. 
Scatter plot shows the ΔGeoMFI of all the analyzed IL-6+ (colored dots) and IL-6- (black dots) samples (left). Rapresentative histograms 
of IL-6+ and IL-6- MM primary cells are also showed (right). c. Gene expression profiles of IL-6 and HES1 in 37 mesenchymal stromal 
cell (MSC) samples from 16 healthy donors and 21 MM cases, alone (8 N-MSC, 9 MM-MSC) or in co-culture with MM1S cell line 
(8 N-MSC, 12 MM-MSC), extracted from an external database (GSE46053) profiled on Affymetrix HG-U133 Plus 2.0 array. Kruskal-
Wallis test was performed to assess statistical significance of differential gene expression profiles between all four MSC groups. Dunn’s 
test and the Benjamini-Hochberg correction were applied for nonparametric pairwise multiple comparisons. Statistical analysis indicates 
a significant p-value for IL-6 in N-MSC and MM-MSC alone groups compared to both co-cultured N-MSC and MM-MSC samples (p 
= 0.0008, p = 0.0018 for N-MSC alone; p = 0.0012, p = 0.0038 for MM-MSC alone), respectively; similarly for HES1 in N-MSC and 
MM-MSC alone compared to both co-cultured N and MM groups, respectively (p = 0.0485, p = 0.0101 for N-MSC alone; p = 0.0135, 
p = 0.0017 for MM-MSC alone). D. Pearson’s correlation plots of IL-6 and HES1 expression levels (log2 scale) in the same data set. E. 
Representative images of IHC staining for HES6 and IL-6 (brown immunoreactivity) in human BOM infiltration by κ light chain myeloma 
(MM) (red immunostaining) at different stages (for each tumor stage, consecutive histological sections were stained with different; bars 
markers represent 100μm for stage I and II and 250μm for stage III) antigens) Stage I MM: HES6 immunoreactivity can be easily detected 
both in neoplastic and in stromal cells; IL-6 immunostaining is detectable in non-neoplastic cells surrounding myelomatous nests (arrows). 
Stage II MM: A more intense HES6 immunoreactivity can be detected in both BM components; IL-6 immunoreactivity can be observed 
also in some MM cells. Stage III MM: in late stages of tumor infiltration, intense HES6 and IL-6 immunoreactivity is appreciable in κ 
light chain immunoreactive MM cells. In this case, to better visualize HES6 and IL-6 immunoreactivity and distribution, single antigens 
immunoreactivity was evaluated individually on each consecutive slide; the same BM areas of the case under study are here compared. F. 
Schematic illustration of the JAGGED-directed mechanisms of autocrine and paracrine IL-6 expression in MM.
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derived inflammatory stimuli in IL-6 production occurring 
in MM cells is needed. 
Overall, these findings support the notion that Notch 
may induce the independency from BM niche and IL-6 
stimulus by promoting the autocrine IL-6 production 
in MM cells, thereby contributing to progression to 
the extramedullary phase. We anticipate that other 
mechanisms of cooperation between the IL-6 and 
Notch pathways may exist since Notch activation may 
compensate IL-6 proliferative signal even in MM cells 
that do not autonomously produce IL-6 (i.e. OPM2, CMA-
03/06, XG-1). 
Beside the possible tumor autonomous production 
of IL-6, BMSCs represent the main source of IL-6 for 
myeloma cells [10-12], therefore we examined whether 
Notch signaling could affect the release of IL-6 from 
BMSCs. Our results showed that both ICN1 and ICN2 are 
able to transactivate IL-6 promoter in the NIH3T3 murine 
fibroblast cell line used as mimic of BMSCs. Moreover, 
in human BMSCs Notch activity was necessary for the 
production of IL-6 protein; indeed, RNA interference of 
NOTCH1 resulted in decreased IL-6 mRNA and protein 
expression in the human line HS5. Accordingly, HS5-
N1kd cells have a reduced ability to support the growth of 
IL-6-dependent XG-1 cell line. 
We investigated if MM cells were able to activate 
Notch signaling in BMSCs through the overexpressed 
JAGGED ligands. Indeed, we observed that HMCLs 
were able to boost the amount of IL-6 produced by 
human (HS5) or murine (NIH3T3) BMSCs. This effect 
was dependent on the expression of JAGGED ligands, 
since the increase in BMSC-derived IL-6 production and 
BMSC support to tumor cell growth were completely 
abrogated upon depletion of JAGGED ligands in the co-
cultured HMCLs. Coherently, Houde et al. stimulated IL-6 
production from the MRC5 lung fibroblast cell line by 
using synthetic JAGGED peptides [40] and by Sethi and 
coworkers demonstrated that breast cancer cell-derived 
JAGGED induced IL-6 production by BMSCs [61].
By ex vivo co-culture systems, we further confirmed 
the ability of CD138+ MM cells to stimulate primary 
BMSCs from MM patients to produce IL-6, as well as 
Notch involvement since the stimulation was abrogated 
by treatment with γ-Secretase inhibitor. 
These results were confirmed by a the evidence 
of a correlation between the expression of IL6 and 
Notch activation in immunohistochemical studies and 
GEP assays. Indeed analyses on BM biopsies from 
MM patients indicated that in early stages of disease, 
IL-6 immunoreactivity was detectable only in discrete 
non-myelomatous cells that expressed IL-6 only when 
in proximity to MM cells. Similarly, Notch activation 
was detected in malignant PCs and in surrounding non-
myelomatous cells. Finally, GEP analysis on mesenchymal 
stromal cells from healthy volunteers and MM patients of 
Garcia Gomez et al. dataset [55] confirmed a correlation 
between the expression of IL-6 and HES1 and additionally 
showed IL-6 and HES1 upregulation upon stimulation 
with the MM1S cell line.
Ovearll, these data attribute to Notch a function in 
MM pathogenesis as a key signaling pathway in tumor-
stroma communication exploited by MM cells to shape the 
BM niche and specifically to increase the release of a key 
cytokine such as IL-6.
In conclusion, this work offers novel insights 
into the role of Notch signaling in MM, providing the 
first experimental evidence that MM-derived JAGGED 
ligands drives IL-6 production by MM cells and 
surrounding BM niche (Figure 6D). Together, these 
findings provide a new paradigm where high-risk MM/
pPCL is characterized by high levels of Notch signaling 
that can partially compensate for lower IL-6 in the 
extramedullary microenvironment, possibly by activating 
IL-6 autonomous production. On the other side, MM 
cells residing in the BM, are still dependent on IL-6, but 
can sustain their own progression by stimulating BMSC-
mediated IL-6 production through JAGGED ligands. The 
present findings strengthen the rationale for Notch-tailored 
therapies in MM providing evidences that knocking down 
MM-derived JAGGED ligands may reduce MM tumor 
burden by decreasing the amount of IL-6 in the BM niche. 
MAtErIALs AND MEtHODs
Gene expression profiling
Highly purified PC samples (CD138 ≥ 90%) from 
the BM of 129 MM and 24 primary plasma cell leukemia 
(pPCL) patients at onset, together with 4 healthy donors 
(N) samples, were previously profiled on the GeneChip 
Human Gene 1.0 ST array (Affymetrix, Santa Clara, 
CA) [62]. Main molecular genomic aberrations (IGH 
translocations, hyperdiploidy, del(13q), del(17p), and 1q 
gain) were investigated in all samples by fluorescence in 
situ hybridization (FISH), as previously described [63] 
and already reported for the entire sample dataset [62]. 
Multiple myeloma samples were stratified in five groups 
according to the translocation/cyclin D (TC) classification 
[50, 64]. Gene expression profiling data were generated as 
described [65], using Brainarray annotation procedure [37, 
66]. The GEP data have been deposited in the NCBI Gene 
Expression Omnibus database (GEO; http//www.ncbi.
nlm.nih.gov/geo; accession No. GSE66293, GSE73452). 
The Institutional Review Board of Fondazione IRCCS 
Policlinico Ca’ Granda, Milano, Italy, approved the design 
of this study. Written informed consent was obtained in 
accordance with the Declaration of Helsinki. 
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cells and treatments
The human MM cell lines XG-1, CMA-03, CMA-
03/06, U266 and OPM2 were cultured in RPMI1640 with 
10% FBS, and for XG-1 cells and CMA-03 cells 1ng/
ml and 10ng/ml IL-6 were added, respectively. NIH3T3 
and human bone marrow stromal (HS5) cell lines 
were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% FBS. The γ-secretase inhibitor, 
DAPT (Sigma-Aldrich, Germany), was reconstitution 
in DMSO and prepared at a final concentration of 25-50 
μM. Recombinant human IL-6 (R&D Systems, USA) 
was resuspended in PBS supplemented with 0,1% w/v 
BSA and used at 10ng/ml. Primary cells were isolated 
from primary patient BM aspirates and MM cells were 
purified using the Human Whole Blood CD138+ Selection 
Kit EasySep (StemCell Technologies). Primary BMSCs 
were isolated as previously reported by Garayoa et al 
[54]. Briefly, mononuclear cells from BM aspirates were 
obtained after density gradient centrifugation using Ficoll-
Paque Premium 1.073 (Sigma Aldrich, USA) and cultured 
in DMEM supplemented with 10% heat-inactivated 
FBS for 3-4 days. Subsequently non-adherent cells were 
removed, whereas stromal cells were selected by their 
adherence to plasticware.
Establishment of stable GFP+ Hs5 cells
The pGIPZ vector (Thermo Scientific) was used 
to stably transduce HS5 cells in order to obtain a GFP-
positive HS5 cell line (GFP+ HS5). The production of 
lentiviral supernatant was performed following the 
manufacturer’s instructions. For transduction, 3×105 HS5 
cells were plated in a 6-well tissue culture plate with 1ml 
of lentiviral supernatant and 4μg/ml of polybrene (Sigma-
Aldrich). After the infection cells were selected using 1μg/
ml puromycin (Sigma-Aldrich).
co-cultures of MM cells and bMscs
For co-culture experiments, MM cell lines were 
seeded in a 24-well plate at a density of 3×105 cells/
ml on a monolayer of GFP+ HS5 or NIH3T3 cells (70-
80% confluence) and cultured for 2 days. For primary 
cell co-cultures, BMSCs, isolated as described above, 
were stained with the fluorescent dye PKH26 (Sigma-
Aldrich) and allowed to adhere for 3 hours. CD138+ cells 
were seeded on the monolayer of PKH+ BMSCs (50-
60% confluence) and cultured for 4 days in the presence/
absence of DAPT.
qrt-Pcr
Total RNA was isolated using the miRneasy kit 
(Qiagen) and cDNA was prepared using RevertAid 
M-MuLV Reverse Transcriptase (ThermoScientific) [67]. 
Quantitative PCR (qPCR) was performed as previously 
described [49, 68]. Primer sequences are reported in Table 
1 (Supplementary Information).
Western blot
Total cells protein were extracted with RIPA lysis 
buffer as previously reported [69]. Protein samples (40 
µg) were run on a 4-12% NuPAGE gel (ThermoScientific), 
transferred onto a nitrocellulose membrane (Biorad), and 
blocked with 5% non-fat milk in TBS-T (20 mM Tris-Cl, 
pH 7.5, 150 mM NaCl, 0.05% Tween-20). Membranes 
were incubated overnight at 4 °C with rabbit anti-
NOTCH2 (1:1000, Cell Signaling), rabbit anti-HES1 
(1:1000, Abcam) or rabbit anti-β-actin (1:5000, Sigma), 
and then with the appropriated HRP-conjugated species-
specific secondary antibody (Pierce Protein Biology). 
Detection was performed by ECL (Biorad) according to 
the manufacturer’s instructions. The signal was detected 
and analyzed by ChemiDoc MP System (Biorad).
rNAi assay
Stealth RNAiTM siRNA system 
(Invitrogen) consisting of small interfering 
RNA (siRNA) molecules targeting NOTCH1 
(CCGCCUUUGUGCUUCUGUUCUUCGU, 
ACGAAGAACAGAAGCACAAAGGCGG), 
IL-6 (UACAUCUUUGGAAUCUUCUCCUGGG, 
CCCAGGAGAAGAUUCCAAAGAUGUA) and 
a scrambled control were used according to the 
manufacturer’s guidelines. The two siRNAs targeting 
JAGGED1 and JAGGED2 were used as previously 
reported [46]. Transfections were performed for 48-
96 hours with 50 nM siRNAs/scrambled control using 
lipofectamine RNAiMAX (Invitrogen). 
Luciferase reporter assay
The pIL6-651 plasmid carrying IL-6 promoter 
[70,71] was a kind gift of Dr. Norifumi Takeda. The 
thymidine kinase promoter-driven Renilla luciferase 
(TK-pRL; Promega Italia s.r.l., Milano, Italy) was used 
for normalization; pcDNA3.1 mock plasmid was from 
Invitrogen (Invitrogen Life Technologies Italia, Italy). 
The plasmids carrying ICN1 and ICN2 were as previously 
described [72,73]. Ten micrograms of total DNA were 
used for electroporation in U266 cells as previously 
reported [49]; ten micrograms of total DNA were 
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transfected in NIH3T3 cells using TurboFect Transfection 
Reagents (Thermo Fisher Scientific). 
All analyses were performed 48h after transfection 
using Dual-Luciferase Reporter Assay System (Promega 
Italia s.r.l., Milano, Italy) according to the manufacturer’s 
directions.
Flow cytometry
Absolute cell counts were determined using the 
volumetric count tool of the BD FACSVerse™ System 
(BD Biosciences, USA). For evaluation of IL-6 expression, 
cells were fixed with 4% formaldehyde, permeabilized in 
0.5% saponin and stained with anti-human IL-6 antibody 
(eBioscience Inc, USA) or isotype matched control. Cells 
were processed using the BD FACSVerse™ System (BD 
Biosciences). For every sample it was measured the 
geometric mean fluorescence intensity subtracted of the 
appropriate isotype control (ΔGeoMFI).
Immunohistochemistry (IHc)
Archival BM biopsies were analyzed from 21 
MM patients diagnosed at the Unit of Pathology, A.O. 
San Paolo, Department of Health Sciences, University 
of Milan, Milan, Italy. BM biopsies were fixed in 10% 
neutral buffered formalin, decalcified, routinely processed 
for conventional histology, and stained with haematoxylin 
and eosin, and Giemsa and Gomori silver impregnation 
techniques. All cases under study had a κ light chain 
phenotype of the neoplastic component; histopathological 
diagnosis was carried out according to the WHO 
classification; tumor stage (extent of BM infiltration by 
myeloma cells) was evaluated as follows: stage I: less 
than 20% (7 cases), stage II: 20-50% (7 cases), stage 
III: >50% (7 cases). Double immunohistochemistry of 
κ-light chain with HES6 or IL-6 was performed by a 
standard avidin-biotin-peroxidase complex technique 
on slides with consecutive serial sections cut from each 
BM biopsy. Antigens were visualized using alkaline 
phosphatase (κ-light chain in red) and diaminobenzidine 
(DAB) (HES6 and IL-6 in brown) as chromogens ([74] 
and Supplementary Materials for details).
statistical analysis
Data are represented as means ± SD from at least 
3 independent experiments. Statistical analyses were 
performed as follows: for single culture and co-culture 
experiments using MM and BMSC cell lines we used two-
tailed Student’s t-test to compare the means of normally 
distributed values and analysis of variance was performed 
by one-way ANOVA with Tukey’s post-test. For co-culture 
experiments on human primary cells one-way ANOVA 
with Bonferroni post-test was performed.
In GEP experiments Kruskal-Wallis test was applied 
to measure the differential expression of the selected genes 
between groups, Dunn’s test was exploited to perform 
nonparametric pairwise multiple comparisons between the 
independent groups and Benjamini-Hochberg correction 
was applied to adjust significance of multiple testing [75, 
76].
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